Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRCT NASDAQ:SLGL NASDAQ:TBPH NASDAQ:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRCTDirect Digital$3.10+5.8%$3.27$2.17▼$172.70$2.31M5.3367,067 shs28,727 shsSLGLSol-Gel Technologies$73.73+4.7%$73.51$6.80▼$97.97$197.82M1.1330,477 shs13,081 shsTBPHTheravance Biopharma$15.58-2.3%$16.27$10.42▼$21.03$821.76M0.17346,907 shs814,822 shsVORVor Biopharma$13.66-6.2%$15.20$3.63▼$65.80$789.49M1.71802,163 shs798,406 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRCTDirect Digital+5.80%-8.82%-22.31%-24.76%-97.26%SLGLSol-Gel Technologies+4.73%-1.03%-2.49%-16.60%+907.79%TBPHTheravance Biopharma-2.26%-5.06%-7.21%+14.06%+39.73%VORVor Biopharma-6.25%-3.12%-1.37%-9.24%+1,365,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRCTDirect Digital$3.10+5.8%$3.27$2.17▼$172.70$2.31M5.3367,067 shs28,727 shsSLGLSol-Gel Technologies$73.73+4.7%$73.51$6.80▼$97.97$197.82M1.1330,477 shs13,081 shsTBPHTheravance Biopharma$15.58-2.3%$16.27$10.42▼$21.03$821.76M0.17346,907 shs814,822 shsVORVor Biopharma$13.66-6.2%$15.20$3.63▼$65.80$789.49M1.71802,163 shs798,406 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRCTDirect Digital+5.80%-8.82%-22.31%-24.76%-97.26%SLGLSol-Gel Technologies+4.73%-1.03%-2.49%-16.60%+907.79%TBPHTheravance Biopharma-2.26%-5.06%-7.21%+14.06%+39.73%VORVor Biopharma-6.25%-3.12%-1.37%-9.24%+1,365,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRCTDirect Digital 1.50ReduceN/AN/ASLGLSol-Gel Technologies 2.60Moderate Buy$110.0049.19% UpsideTBPHTheravance Biopharma 2.75Moderate Buy$21.8340.14% UpsideVORVor Biopharma 2.82Moderate Buy$42.25209.30% UpsideCurrent Analyst Ratings BreakdownLatest SLGL, DRCT, TBPH, and VOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026VORVor Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/29/2026SLGLSol-Gel Technologies TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/27/2026TBPHTheravance Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/22/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Sell (D+)5/18/2026VORVor Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.005/15/2026SLGLSol-Gel Technologies Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/14/2026VORVor Biopharma WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$15.00 ➝ $18.005/11/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/8/2026TBPHTheravance Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)4/30/2026VORVor Biopharma Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/24/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRCTDirect Digital$33.22M0.07N/AN/A($18.82) per share-0.16SLGLSol-Gel Technologies$19.39M10.68N/AN/A$8.19 per share9.00TBPHTheravance Biopharma$107.46M7.47N/AN/A$5.86 per share2.66VORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRCTDirect Digital-$18.95M-$201.62N/AN/AN/A-65.75%N/A-59.57%8/4/2026 (Estimated)SLGLSol-Gel Technologies-$6.13M-$0.34N/AN/AN/A-5.66%-3.17%-2.58%8/21/2026 (Estimated)TBPHTheravance Biopharma$105.89M$2.207.0855.64N/A104.34%18.84%10.94%8/11/2026 (Estimated)VORVor BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest SLGL, DRCT, TBPH, and VOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/28/2026Q1 2026SLGLSol-Gel Technologies-$2.86-$1.31+$1.55$1.31$0.90 million$0.11 million5/11/2026Q4 2025DRCTDirect Digital-$7.74-$7.25+$0.49-$10.32$6.82 million$6.68 million5/7/2026Q1 2026TBPHTheravance Biopharma$0.0280-$0.10-$0.1280-$0.10$17.78 million$17.70 million3/31/2026Q4 2025TBPHTheravance BiopharmaN/A-$0.10N/A-$0.10N/A$17.70 million3/30/2026Q4 2025VORVor BiopharmaN/A$307.61N/A$307.61N/AN/A3/19/2026Q4 2025SLGLSol-Gel Technologies$0.39-$1.07-$1.46-$1.06$6.50 million$0.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDRCTDirect DigitalN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRCTDirect DigitalN/A0.160.16SLGLSol-Gel TechnologiesN/A8.848.84TBPHTheravance BiopharmaN/A13.1413.14VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRCTDirect Digital4.02%SLGLSol-Gel Technologies26.18%TBPHTheravance Biopharma99.10%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipDRCTDirect Digital25.57%SLGLSol-Gel Technologies66.51%TBPHTheravance Biopharma7.65%VORVor Biopharma0.27%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRCTDirect Digital60743,000553,000Not OptionableSLGLSol-Gel Technologies502.81 million941,000No DataTBPHTheravance Biopharma11051.55 million47.61 millionOptionableVORVor Biopharma14054.19 million54.04 millionN/ASLGL, DRCT, TBPH, and VOR HeadlinesRecent News About These CompaniesVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 1 at 5:00 PM | globenewswire.comVor Bio to Participate in the 2026 Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comVor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 26, 2026 | americanbankingnews.comWe're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash WiselyMay 15, 2026 | finance.yahoo.comAnalysts Are Bullish on These Healthcare Stocks: Protara Therapeutics (TARA), Vor Biopharma (VOR)May 14, 2026 | theglobeandmail.comVor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of MedicineMay 14, 2026 | globenewswire.comVor Biopharma: Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | finanznachrichten.deVor Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | globenewswire.comWall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to TradeMay 7, 2026 | zacks.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 | globenewswire.comVor Biopharma (NASDAQ:VOR) Director Sells $2,711,856.51 in StockApril 22, 2026 | insidertrades.comDoes Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?April 20, 2026 | zacks.comRa Capital Management, L.P. Sells 53,644 Shares of Vor Biopharma (NASDAQ:VOR) StockApril 16, 2026 | insidertrades.comRa Capital Management, L.P. Sells 828 Shares of Vor Biopharma (NASDAQ:VOR) StockApril 11, 2026 | insidertrades.comVor Biopharma: It's A Game Of Wait And SeeApril 8, 2026 | seekingalpha.comVor Biopharma (NASDAQ:VOR) Director Sells $4,739,800.00 in StockApril 7, 2026 | insidertrades.comVor Biopharma (VOR) Upgraded to Buy: Here's WhyApril 2, 2026 | zacks.comWall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should KnowApril 2, 2026 | zacks.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 1, 2026 | globenewswire.comJefferies initiates coverage of Vor Biopharma (VOR) with buy recommendationMarch 31, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLGL, DRCT, TBPH, and VOR Company DescriptionsDirect Digital NASDAQ:DRCT$3.10 +0.17 (+5.80%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$3.06 -0.04 (-1.13%) As of 07:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Direct Digital Holdings, Inc. operates as an end-to-end full-service programmatic advertising platform. The company's platform primarily focuses on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy- and sell-side of the digital advertising ecosystem. It serves various industry verticals, such as travel, healthcare, education, financial services, consumer products, and other sectors with a focus on small and mid-sized businesses. The company was founded in 2018 and is headquartered in Houston, Texas.Sol-Gel Technologies NASDAQ:SLGL$73.73 +3.33 (+4.73%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$67.49 -6.24 (-8.46%) As of 07:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.Theravance Biopharma NASDAQ:TBPH$15.58 -0.36 (-2.26%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$15.68 +0.10 (+0.64%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.Vor Biopharma NASDAQ:VOR$13.66 -0.91 (-6.25%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$13.78 +0.12 (+0.88%) As of 07:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod Dollar General Signals Reversal With 60% Rebound Potential Kohl's Stock Soars After Better-Than-Feared Quarter Credo Technologies Paved a Path to a $300 Price Point MGM Buyout: The House Doesn't Always Win Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence? FirstCash Turns Pawn Into a Growth Machine HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
